(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $28.00
发出时间: 13 Feb 2024 @ 22:35
回报率: -19.29%
上一信号: Feb 13 - 00:18
上一信号:
回报率: -7.41 %
Live Chart Being Loaded With Signals
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE)...
Stats | |
---|---|
今日成交量 | 55 237.00 |
平均成交量 | 87 353.00 |
市值 | 1.22B |
EPS | $0 ( 2024-04-03 ) |
下一个收益日期 | ( $-0.560 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.04 |
ATR14 | $0.176 (0.78%) |
音量 相关性
Pharvaris N.V. 相关性 - 货币/商品
Pharvaris N.V. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-252 271 (0.00 %) |
EPS: | $-2.57 |
FY | 2023 |
营收: | $0 |
毛利润: | $-252 271 (0.00 %) |
EPS: | $-2.57 |
FY | 2022 |
营收: | $0 |
毛利润: | $-150 186 (0.00 %) |
EPS: | $-2.27 |
Financial Reports:
No articles found.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。